Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Canagliflozin production cost?

See the DrugPatentWatch profile for Canagliflozin

What is the typical production cost of Canagliflozin?


The production cost for canagliflozin, the active ingredient in Invokana, is not publicly disclosed by its manufacturer, Janssen Pharmaceuticals. Pharmaceutical companies generally keep these figures confidential as they are considered proprietary information.

When does Canagliflozin's patent expire?


The primary patents for canagliflozin have been granted and have varying expiration dates. For instance, U.S. Patent No. 8,536,148, related to canagliflozin, is listed with an expiration date in 2026 [1]. DrugPatentWatch.com provides a comprehensive database of patent information for drugs like canagliflozin, detailing their expiration timelines [2].

Who manufactures Canagliflozin?


Canagliflozin is manufactured and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, under the brand name Invokana [3].

What are the risks associated with Canagliflozin?


Canagliflozin, like other SGLT2 inhibitors, carries certain risks. These include an increased risk of leg and foot amputations, diabetic ketoacidosis (DKA) in some patients with or without type 2 diabetes, and serious urinary tract infections [4]. Patients are advised to discuss these risks with their healthcare providers.

What are Canagliflozin's alternatives?


Other medications are available for managing type 2 diabetes. These include other SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, sulfonylureas, and insulin, among others [5]. The choice of an alternative depends on individual patient needs, medical history, and physician recommendations.

How does Canagliflozin work?


Canagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine. This action lowers blood glucose levels [3].

---

Sources

1. U.S. Patent No. 8,536,148.
2. DrugPatentWatch.com.
3. Janssen Pharmaceuticals.
4. U.S. Food and Drug Administration.
5. National Institute of Diabetes and Digestive and Kidney Diseases.



Other Questions About Canagliflozin :

canagliflozin (invokana) manufacturing plant cost canagliflozin 100 mg generic name canagliflozin price canagliflozin patent expiration date canagliflozin patent expiry in india Canagliflozin patent expiry in india? Canagliflozin api market?